Humedics GmbH

Humedics GmbH is a Germany-based Medtech company specializing in innovative liver diagnostics through its flagship product, the LiMAx test, designed for assessing liver function in various medical contexts. Founded in Germany, Humedics GmbH focuses on liver diagnostics, developing the LiMAx test for functional analysis of liver health. The company raised EUR 6. 3 million in SERIES C funding on September 29, 2014, led by Seventure and Vesalius BioCapital, with participation from BioMed Ventures, High-Tech Gruenderfonds, KfW Banking Group, Peppermint VenturePartners, and Ventegis Capital.

The total amount raised to date is EUR 6. 3 million, with a current valuation of EUR 14. 114 mn. Humedics GmbH is a Berlin-based Medtech company renowned for its innovative LiMAx test, a revolutionary functional liver diagnostic tool.

The LiMAx test is designed to accurately assess liver function in various medical contexts, including liver surgery, liver transplantation, hepatology, and oncology. It enables healthcare professionals to make informed clinical decisions, enhancing patient safety and treatment outcomes. The LiMAx test serves a diverse client base, including hospitals, surgical units, and liver care specialists across multiple geographical markets in Europe and beyond. By providing precise liver function capacity analysis, Humedics addresses critical needs in liver-related health conditions, thus improving patient management strategies.

Humedics generates revenue primarily through the sales of its flagship product, the LiMAx test, which is utilized by medical institutions and healthcare providers. In 2021, the company reported a revenue of EUR 1,167,009. 30 and an EBITDA of EUR -186,900. 80.

The company’s transaction structure includes direct sales to hospitals and clinics, supported by partnerships for broader distribution. Through its registered trademarks, LiMAx and Humedics, the firm maintains a strong market presence while focusing on enhancing liver diagnostic capabilities. Humedics GmbH aims to utilize the recent SERIES C funding of EUR 6. 3 million to support its growth initiatives.

Plans include expanding the market reach of the LiMAx test into new geographic areas and enhancing product offerings through ongoing research and development. Specific targeted expansions are likely to focus on European markets beyond Germany, improving access to innovative liver diagnostics. The funding will assist in bringing new products to market, although specific upcoming product launches have not been detailed.